Prostate cancer is a hormone-dependent disease that is dependent on endogenous androgens to advance and proliferate. More than 90 percent of all prostate cancers are discovered in the local and regional stage and are prescribed various treatments that result in significant morbidity (side-effects).
Prostate cancer is the most common cancer in men in Europe and North America. In the USA, prostate cancer continues to have the highest incidence rate and the third highest mortality rate of any cancer for men. According to Global Cancer Statistics, there were more than 190,000 new cases of prostate cancer in 2009 and nearly 30,000 men died of this disease the same year in the USA only. Prostate cancer constitutes about 33 percent of all male cancers in USA. Globally, prostate cancer is the sixth most common cancer in the number of new cases (incidence), and the third most common among men. Approximately 1 000 000 new cases of prostate cancer were registered, globally, in 2009. The incidence will increase in the future as the population live longer ("graying population"). In 2030 it is estimated that about 20 % of the population of men › 65 years will suffer from prostate cancer (today 12.4 %).